DelMar Pharmaceuticals, Inc. Human Resources Contracts & Agreements
29 Contracts & Agreements
- Bonus & Incentive Agreements (8 contracts)
- Consulting Agreements (8)
- Employment Agreements (12)
- Separation Agreements (1)
- TuHURA Biosciences, Inc. 2024 Equity Incentive Plan (Filed With SEC on October 21, 2024)
- Amendment to Executive Employment Agreement, dated October 4, 2024, by and between the Company and Robert E. Hoffman (Filed With SEC on October 7, 2024)
- Employment Agreement, dated December 19, 2023, between TuHURA Biosciences, Inc. and Dennis Yamashita (Filed With SEC on May 13, 2024)
- Second Amended and Restated Employment Agreement, dated March 29, 2024, between TuHURA Biosciences, Inc. and James Bianco, M.D (Filed With SEC on May 13, 2024)
- Second Amended and Restated Employment Agreement, dated March 29, 2024, between TuHURA Biosciences, Inc. and Dan Dearborn (Filed With SEC on May 13, 2024)
- Amendment to the 2017 Omnibus Equity Incentive Plan of Kintara Therapeutics, Inc (Filed With SEC on September 27, 2022)
- Separation and General Release Agreement between the Company and Saiid Zarrabian, dated May 20, 2022 (Filed With SEC on May 24, 2022)
- Second Amended Employment Agreement, dated November 8, 2021, by and between the Company and Saiid Zarrabian (Filed With SEC on November 12, 2021)
- Executive Employment Agreement, dated November 8, 2021, by and between the Company and Robert Hoffman (Filed With SEC on November 12, 2021)
- Amendment to the 2017 Omnibus Equity Incentive Plan of Kintara Therapeutics, Inc (Filed With SEC on September 28, 2021)
- First Amended Executive Employment Agreement, by and between Kintara Pharmaceuticals, Inc. and Saiid Zarrabian (Filed With SEC on November 12, 2020)
- Amendment to the 2017 Omnibus Equity Incentive Plan of Kintara Therapeutics, Inc (Filed With SEC on September 18, 2020)
- Amendment No. 3 to Employment Agreement, dated as of April 6, 2020, by and between Adgero Biopharmaceuticals Holdings, Inc. and Steven J. Rychnovsky (Filed With SEC on June 16, 2020)
- Amendment No. 2 to Employment Agreement, dated as of April 6, 2018, by and between Adgero Biopharmaceuticals Holdings, Inc. and Steven J. Rychnovsky (Filed With SEC on June 16, 2020)
- Employment Agreement, dated as of April 8, 2016, by and between Adgero Biopharmaceuticals Holdings, Inc. and Steven J. Rychnovsky (Filed With SEC on June 16, 2020)
- Amended and Restated Employment Agreement, dated as of March 1, 2018, by and between Adgero Biopharmaceuticals Holdings, Inc. and John Liatos (Filed With SEC on June 16, 2020)
- Amendment to the 2017 Omnibus Equity Incentive Plan of DelMar Pharmaceuticals, Inc (Filed With SEC on September 9, 2019)
- Employment Agreement, dated May 21, 2018, by and between DelMar Pharmaceuticals, Inc. and Mr. Zarrabian (Filed With SEC on May 22, 2018)
- Form of DelMar Pharmaceuticals, Inc. 2017 Omnibus Equity Incentive Plan Option Grant Agreement (Filed With SEC on May 15, 2018)
- AMENDMENTTO CONSULTING AGREEMENT (Filed With SEC on February 10, 2017)
- CONSULTING AGREEMENT (Filed With SEC on April 10, 2015)
- CONSULTING AGREEMENT (Filed With SEC on April 10, 2015)
- CONSULTING AGREEMENT (Filed With SEC on April 10, 2015)
- Consulting Agreement, dated February 1, 2013, between DelMar (BC) and Scott Praill (Filed With SEC on March 14, 2013)
- Consulting Agreement, dated August 1, 2011, between DelMar (BC) and William Garner (Filed With SEC on March 14, 2013)
- Consulting Agreement, dated August 1, 2011, between DelMar (BC) and Dennis Brown (Filed With SEC on March 14, 2013)
- Consulting Agreement, dated August 1, 2011, between DelMar (BC) and Jeffrey Bacha (Filed With SEC on March 14, 2013)
- Amendment No. 1 to Employment Agreement, Incentive Stock Option Grant Agreement and Nonqualified Stock Option Grant Agreement, dated as of February 8, 2017, by and between Adgero... (Filed With SEC on June 16, 2020)
- DelMar Pharmaceuticals, Inc. 2017 Omnibus Equity Incentive Plan (As Amended and Restated Effective as of February 1, 2018) (Filed With SEC on February 14, 2018)
